Osteoporosis drug safety checked in indian women
NCT ID NCT06079476
First seen Nov 03, 2025 · Last updated Jun 23, 2026 · Updated 29 times
Summary
This study tested the safety and tolerability of romosozumab (Evenity) in 100 postmenopausal women in India who have osteoporosis and a high risk of bone fractures. Researchers monitored side effects, serious adverse events, and changes in lab tests and vital signs. They also measured bone density improvements in the spine and hip.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTMENOPAUSAL OSTEOPOROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Apollo Hospital
New Delhi, National Capital Territory of Delhi, 110076, India
-
Christain Medical College
Vellore, Tamil Nadu, 632004, India
-
King Edward Memorial Hospital And Seth Gordhandas Sunderdas Medical College
Mumbai, Maharashtra, 400012, India
-
King Georges Medical University
Lucknow, Uttar Pradesh, 226 003, India
-
MGM Healthcare
Chennai, Tamil Nadu, 600 029, India
-
MS Ramaiah Medical College and Hospitals
Bangalore, Karnataka, 560054, India
-
Post Graduate Institute of Medical Education and Research
Chandigarh, Punjab, 160 012, India
-
Sancheti Institute for Orthopedics and rehabilitation
Pune, Maharashtra, 411005, India
-
Sir Ganga Ram Hospital
New Delhi, National Capital Territory of Delhi, 110060, India
-
Stavya Spine Hospital and Research Institute SSHRI
Ahmedabad, Gujarat, 380 007, India
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
romosozumab (Evenity)
What this could lead to
If successful, this study could confirm that romosozumab is a safe and tolerable option for Indian women with osteoporosis, helping reduce fracture risk.
What could go wrong
This is a small, single-arm, completed Phase 4 study with no placebo group, so results may not be generalizable. Safety findings are limited to 100 participants.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.